Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Hormone Receptor Positive (HR+) Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02941926
What this trial is testing

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 3,246
Large-scale testing (Phase 3)Study completedNCT02278120
What this trial is testing

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 672
Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Testing effectiveness (Phase 2)UnknownNCT03910712
What this trial is testing

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

Who this might be right for
Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast+3 more
Peking Union Medical College Hospital 250
Not applicableStudy completedNCT03921866
What this trial is testing

UK Ibrance Patient Program (IPP) Study

Who this might be right for
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Pfizer 191
Testing effectiveness (Phase 2)Ended earlyNCT02990845
What this trial is testing

Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Premenopausal Breast Cancer
National Taiwan University Hospital 16
Testing effectiveness (Phase 2)Looking for participantsNCT06974604
What this trial is testing

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

Who this might be right for
Breast NeoplasmsLung Neoplasms
Brown University 60
Testing effectiveness (Phase 2)Ended earlyNCT03519178
What this trial is testing

PF-06873600 in People With Cancer

Who this might be right for
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Pfizer 155
Testing effectiveness (Phase 2)UnknownNCT02000193
What this trial is testing

Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-sen University 58
Not applicableStudy completedNCT05584644
What this trial is testing

Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Neoplasms+2 more
Pfizer 150
Testing effectiveness (Phase 2)Ended earlyNCT04227327
What this trial is testing

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

Who this might be right for
Advanced Breast Cancer
University of Milano Bicocca 31
Testing effectiveness (Phase 2)Study completedNCT03056755
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 383
Testing effectiveness (Phase 2)Study completedNCT04505826
What this trial is testing

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
Olema Pharmaceuticals, Inc. 153
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Early research (Phase 1)Active Not RecruitingNCT07557004
What this trial is testing

SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

Who this might be right for
HR+ / HER2- Advanced Breast Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 30
Early research (Phase 1)Study completedNCT03854903
What this trial is testing

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor Positive Breast Cancer
Georgetown University 19
Testing effectiveness (Phase 2)Study completedNCT02675231
What this trial is testing

Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CancerHER-2 Positive Breast Cancer
Eli Lilly and Company 237
Not applicableStudy completedNCT04708860
What this trial is testing

Feasibility of Fasting & Exercise in Pts With HR+ MBC

Who this might be right for
Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 30
Post-approval studies (Phase 4)UnknownNCT05809024
What this trial is testing

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Who this might be right for
Locally Advanced Breast CancerHormone Receptor Positive，HER2-negative Breast Cancer
Yongsheng Wang 100
Early research (Phase 1)Study completedNCT05159518
What this trial is testing

PRT2527 in Participants With Advanced Solid Tumors

Who this might be right for
SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast Cancer+2 more
Prelude Therapeutics Incorporated 30
Next Page